Last reviewed · How we verify
18F-rhPSMA-7.3
18F-rhPSMA-7.3 is a PET imaging agent / radiopharmaceutical Small molecule drug developed by Hackensack Meridian Health. It is currently FDA-approved for PET imaging of PSMA-positive lesions in men with prostate cancer.
18F-rhPSMA-7.3 is a fluorine-18 labeled imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable PET imaging detection.
18F-rhPSMA-7.3 is a fluorine-18 labeled imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable PET imaging detection. Used for PET imaging of PSMA-positive lesions in men with prostate cancer.
At a glance
| Generic name | 18F-rhPSMA-7.3 |
|---|---|
| Sponsor | Hackensack Meridian Health |
| Drug class | PET imaging agent / radiopharmaceutical |
| Target | PSMA (prostate-specific membrane antigen) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This radiopharmaceutical is a positron emission tomography (PET) tracer composed of a recombinant human PSMA-targeting ligand labeled with the radioactive isotope fluorine-18. It localizes to PSMA-expressing cells, primarily in prostate cancer lesions, allowing clinicians to visualize and detect metastatic disease and guide treatment decisions.
Approved indications
- PET imaging of PSMA-positive lesions in men with prostate cancer
Common side effects
- Radiation exposure (inherent to PET imaging)
- Injection site reactions
Key clinical trials
- Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy (PHASE3)
- Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment (NA)
- Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial (PHASE2)
- Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial (EARLY_PHASE1)
- Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection (PHASE1, PHASE2)
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance (PHASE2)
- Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer (PHASE1)
- Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-rhPSMA-7.3 CI brief — competitive landscape report
- 18F-rhPSMA-7.3 updates RSS · CI watch RSS
- Hackensack Meridian Health portfolio CI
Frequently asked questions about 18F-rhPSMA-7.3
What is 18F-rhPSMA-7.3?
How does 18F-rhPSMA-7.3 work?
What is 18F-rhPSMA-7.3 used for?
Who makes 18F-rhPSMA-7.3?
What drug class is 18F-rhPSMA-7.3 in?
What development phase is 18F-rhPSMA-7.3 in?
What are the side effects of 18F-rhPSMA-7.3?
What does 18F-rhPSMA-7.3 target?
Related
- Drug class: All PET imaging agent / radiopharmaceutical drugs
- Target: All drugs targeting PSMA (prostate-specific membrane antigen)
- Manufacturer: Hackensack Meridian Health — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for PET imaging of PSMA-positive lesions in men with prostate cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing